SOPHiA DDM Platform will bring next-generation sequencing in-house and help further research on hematologic malignancies
The SOPHiA DDM Platform is a cloud-based platform that uses AI with patented technologies to synthesise NGS data. (Credit: National Cancer Institute on Unsplash)
SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced Centre Hospitalier de Bastia is live on the SOPHiA DDM Platform. Centre Hospitalier de Bastia, a general hospital located in the city of Bastia, on the French island of Corsica, is using the SOPHiA DDM Platform to introduce in-house next-generation sequencing (NGS), which will support their clinical oncology research and facilitate deeper insights into hematologic malignancies.
Hematologic cancers such as leukemia, lymphoma, and myeloma begin in the cells of the immune system or in blood-forming tissue, such as the bone marrow. These types of cancers, also called blood cancers, represent the fourth most frequent cancer type in the developed world and can move fast.
The SOPHiA DDM Platform is a cloud-based platform that uses Artificial Intelligence (AI) with patented technologies to synthesize next-generation sequencing (NGS) data; this is key when categorizing disease-associated mutations. The SOPHiA DDM Platform will enable Centre Hospitalier de Bastia to build in-house expertise, further their molecular testing capabilities, and help to accelerate their research on hematologic malignancies and potentially other cancer types.
By using the SOPHiA DDM Platform, Centre Hospitalier de Bastia will be able to synchronize its testing and reporting capabilities across the four units of the Pole technique et Medico-Technique center and the public health department; this will support expedited analysis and better equip researchers, as they work to practice data-driven medicine.
“Next-generation sequencing has become the gold standard in genomic testing, specifically as it relates to fast-moving and sometimes complex cancers like hematologic malignancies,” said Kevin Puylaert, VP Business Development and Marketing, SOPHiA GENETICS. “By using the SOPHiA DDM Platform, Centre Hospitalier de Bastia is enhancing their research capabilities and connecting with world-class institutions globally, making precision medicine a reality in Corsica.”
Source: Company Press Release